Fluorouracil clinical trials
Also written 5-FU, Adrucil, Efudex and 5-Fluoruracil.
Counted the way a researcher would: Fluorouracil with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Fluorouracil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Fluorouracil studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Apr 1962 · FLUOROURACIL · NDA 012209 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Other names
- 5-Fluoruracil
- 3
In one entry with another drug
Given together, or one or the other
Studies by the year they started
755 studies that test it; most in 2006 (36)
| Year | Studies |
|---|---|
| 1990 | 2 |
| 1991 | 1 |
| 1993 | 4 |
| 1994 | 4 |
| 1995 | 3 |
| 1996 | 9 |
| 1997 | 18 |
| 1998 | 22 |
| 1999 | 27 |
| 2000 | 30 |
| 2001 | 32 |
| 2002 | 28 |
| 2003 | 31 |
| 2004 | 29 |
| 2005 | 23 |
| 2006 | 36 |
| 2007 | 32 |
| 2008 | 29 |
| 2009 | 26 |
| 2010 | 23 |
| 2011 | 31 |
| 2012 | 25 |
| 2013 | 17 |
| 2014 | 28 |
| 2015 | 23 |
| 2016 | 21 |
| 2017 | 14 |
| 2018 | 19 |
| 2019 | 22 |
| 2020 | 22 |
| 2021 | 23 |
| 2022 | 17 |
| 2023 | 15 |
| 2024 | 26 |
| 2025 | 20 |
| 2026 | 23 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 80 · Other 684
National Cancer Institute (NCI) (50) · M.D. Anderson Cancer Center (20) · Memorial Sloan Kettering Cancer Center (19) · Sanofi (15) · Sun Yat-sen University (14) · Alliance for Clinical Trials in Oncology (13) · European Organisation for Research and Treatment of Cancer - EORTC (13) · SWOG Cancer Research Network (12)
Often tested with
Tested in the same studies.
Oxaliplatin (241) · Leucovorin (223) · Cisplatin (156) · Irinotecan (145) · Docetaxel (95) · Paclitaxel (72) · Bevacizumab (57) · Gemcitabine (57)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
- Capecitabine is a prodrug of it, counted here with related medicines source
- Tegafur is a prodrug of it, counted here with related medicines source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 24 phase 3 studies under way
Fluorouracil is the comparator. A study of two new drugs counts under both.
- 4Paclitaxel · Gruppo Oncologico del Nord-Ovest, NRG Oncology · next primary completion Jan 2029
- 3Gemcitabine · NRG Oncology, Sun Yat-sen University · next primary completion Jan 2029
- 2Pembrolizumab · Merck Sharp & Dohme LLC, Astellas Pharma Global Development, Inc. · next primary completion Sep 2028
- 2Albumin-Bound Paclitaxel · Gruppo Oncologico del Nord-Ovest, Shanghai Jiao Tong University School of Medicine · next primary completion Jan 2029
- 2Toripalimab · Hutchison Medipharma Limited, Shanghai Jiao Tong University School of Medicine
- 1Ipilimumab · Bristol-Myers Squibb
- 1Nivolumab · Bristol-Myers Squibb
- 1Daraxonrasib · Revolution Medicines, Inc.
Reaching primary completion within a year · 35, 4 in phase 3
Studies that test Fluorouracil, phase 3 first.
- Dec 2026Paediatric Hepatic International Tumour TrialPhase 3 · University of Birmingham
- Dec 2026Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal CancerPhase 3 · Karolinska University Hospital
- Jan 2027Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic CancerPhase 3 · Erasmus Medical Center
- Mar 2027HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic CancerPhase 3 · Fudan University
- Nov 2026Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative ManagementPhase 2 · Memorial Sloan Kettering Cancer Center
- Dec 2026Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Dec 2026Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and BevacizumabPhase 2 · AbbVie
- Dec 2026A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of BreastPhase 1 · Shanghai Jiao Tong University School of Medicine
- Dec 2026Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric CancerPhase 2 · The First Affiliated Hospital of Zhengzhou University
- Dec 2026A Irinotecan Liposome Trial of in Advanced Neuroendocrine CarcinomaPhase 4 · Beijing GoBroad Hospital
Studies
Open first, then newest update. How each study uses Fluorouracil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 764
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesRecruitingPhase 1National Cancer Institute (NCI)NCT04847063Written as 5-Fluorouracil
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Fluorouracil
- A Study of YL242 in Subjects With Advanced Solid TumorsRecruitingPhase 1/2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07197827Written as YL242; 5-FU; LV
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Fluorouracil
- Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal CancerRecruitingPhase 1Jonsson Comprehensive Cancer CenterNCT04703101Written as Fluorouracil
- Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract CancerNot yet recruitingPhase 3Zhai WenlongNCT07916844Written as 5-Fluorouracil
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingPhase 2AstraZenecaNCT07069712Written as 5-Fluorouracil (5-FU)
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerRecruitingPhase 2Fox Chase Cancer CenterNCT07908979Written as Fluorouracil
- SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC TrialRecruitingPhase 2Northwestern UniversityNCT07748611Written as Fluorouracil
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingPhase 2SWOG Cancer Research NetworkNCT04205968Written as Fluorouracil
- Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal CancerRecruitingPhase 1National Cancer Institute (NCI)NCT06654037Written as Fluorouracil
- NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT04615013Written as Fluorouracil
- DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic CancerRecruitingPhase 1/2Ohio State University Comprehensive Cancer CenterNCT07705919Written as Fluorouracil
- Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Mayo ClinicNCT06078709Written as Fluorouracil
- Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of EpendymomaNot yet recruitingPhase 1/2Children's Oncology GroupNCT07848568Written as Fluorouracil
- NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar TrialRecruitingPhase 2Roswell Park Cancer InstituteNCT06821997Written as Fluorouracil
- Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07831993Written as Fluorouracil
- A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract TumorsRecruitingPhase 4Zhai WenlongNCT07790445Written as Oxaliplatin + 5-Fluorouracil/Leucovorin
- Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07797816Written as Fluorouracil
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerRecruitingPhase 1City of Hope Medical CenterNCT04329494Written as Fluorouracil
See all 764 studies that test Fluorouracil →
Given beside what is tested · 720 — Fluorouracil is usual care or a partner of the new treatment
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT05863195Written as Fluorouracil
- 2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal CancersRecruitingPhase 2Emory UniversityNCT03800693Written as Fluorouracil
- A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsRecruitingPhase 1/2Astellas Pharma Global Development, Inc.NCT07730021Written as 5-fluorouracil
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)RecruitingPhase 3GenmabNCT07775287Written as 5-FU
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07793942Written as 5-Fluorouracil
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07829783Written as 5-FU
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06469944Written as 5-Fluorouracil (5-FU)
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06780111Written as 5-Fluorouracil (5-FU)
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07024615Written as 5-FU
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06997497Written as 5-Fluorouracil
- Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaRecruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT05688215Written as Fluorouracil
- A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07673887Written as 5-FU
- A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerNot yet recruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07915921Written as Fluorouracil (5-FU)
- A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line TherapyRecruitingPhase 1/2Shenzhen Majory Biotechnology Co., Ltd.NCT07235202Written as Irinotecan Liposome Injection combined with 5-FU/LV
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingPhase 3Revolution Medicines, Inc.NCT07621718Written as 5-Fluorouracil
- A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.RecruitingPhase 3AstraZenecaNCT07877818Written as FLOT Chemotherapy
- Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07662031Written as 5-Fluorouracil (5-FU)
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT06901531Written as 5-fluorouracil (5-FU)
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT TrialRecruitingPhase 3City of Hope Medical CenterNCT07271355Written as Fluorouracil
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsRecruitingPhase 1PfizerNCT07318805Written as Fluorouracil
Showing 20 of 720.
As the comparator · 107 — what is tested is compared with Fluorouracil
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialRecruitingPhase 2National Cancer Institute (NCI)NCT06770582Written as Fluorouracil
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerRecruitingPhase 1/2Janssen Research & Development, LLCNCT05379595Written as Fluorouracil
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07566156Written as Fluorouracil
- A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2AbbVieNCT07744126Written as Fluorouracil
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2RecruitingPhase 3AstraZenecaNCT07431281Written as 5-Fluorouracil
- Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic CancerRecruitingPhase 3Eleison Pharmaceuticals LLC.NCT01954992Written as Fluorouracil
- First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingPhase 2Qilu Hospital of Shandong UniversityNCT06730373Written as 5-FU
- Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCRecruitingPhase 3Universität des SaarlandesNCT07026474Written as cisplatin + 5-fluorouracil (5FU)
- A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07676162Written as SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab
- Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.RecruitingPhase 3Gruppo Oncologico del Nord-OvestNCT06897644Written as 5-FU (5-fluorouracil)
- A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic ChemotherapyNot yet recruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07803783Written as 5 Fluorouracil
- Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaNot yet recruitingPhase 3Gruppo Oncologico del Nord-OvestNCT07763171Written as CDDP, 5 Fu
- A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailureRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07606599Written as Fluorouracil
- A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07582315Written as Fluorouracil
- A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine CarcinomaNot yet recruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07595913Written as 5-fluorouracil, Calcium folinate and Irinotecan
- Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerRecruitingPhase 3AkesoNCT07412613Written as 5- Fluorouracil
- Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or MutationsNot yet recruitingPhase 3TransThera Sciences (Nanjing), Inc.NCT07328919Written as Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabine
- 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin CancerRecruitingPhase 2/3Boston UniversityNCT05381597Written as 5-fluorouracil cream
- A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant MetastasesRecruitingPhase 3Rakuten Medical, Inc.NCT06699212Written as 5-fluorouracil
- Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LVRecruitingPhase 1/2Dai, GuanghaiNCT06782685Written as 5-FU
Showing 20 of 107.
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Results posted3
- Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaNov 4, 2026NCT04752696
- NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary CancerOct 27, 2026NCT04005339
- FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic CancerOct 21, 2026NCT04141995
Stopped1
Newly registered2
Codes
What other systems call Fluorouracil · ClinicalTrials.gg INT007511
- MeSH (NLM) D005472FluorouracilConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) U3P01618RTFLUOROURACILConfirmed FDA, NLM, Wikidata
- RxNorm 4492Confirmed FDA, Wikidata
- Wikidata Q238512fluorouracilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C505FluorouracilOne source FDA
- DrugBank DB00544One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005472 | Fluorouracil | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | U3P01618RT | FLUOROURACIL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 4492 | — | Confirmed FDA, Wikidata |
| Wikidata | Q238512 | fluorouracil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C505 | Fluorouracil | One source FDA |
| DrugBank | DB00544 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.